Xenetic Biosciences is trading 14.47% higher at $2.05, with biotech-sector strength offering support rather than a confirmed company-specific catalyst.
- The biotech sector is up 2.18% during the regular session.
- No October 28 company announcement was identified in the available news results.
- The company’s most recent listed announcement, dated October 15, was about the first patient dosed in a study evaluating systemic DNase with CAR T cells; it is not a new event today.